Mitoguazone therapy in patients with refractory or relapsed AIDS- related lymphoma: Results from a multicenter phase II trial

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 1094-1103

  Levine, A M ^a   Tulpule, A ^a   Tessman, D ^a   Kaplan, L ^a   Giles, F ^a   Luskey, B D ^a   Scadden, D T ^a   Northfelt, D W ^a   Silverberg, I ^a   Wernz, J ^a   Espina, B ^a   Von Hoff, D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; METHOTREXATE; MITOGUAZONE; PREDNISONE; SURAMIN; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOMNOLENCE; THROMBOCYTOPENIA; VASODILATATION;

EID: 0031044608     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.1094     Document Type: Article

References (41)

1. Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 36:1S-15S. 1987 (Suppl 1S)
2. Biggar RJ, Rabkin CS: The epidemiology of acquired immunodeficiency syndrome-related lymphomas. Curr Opin Oncol 4:883-893, 1992
3. Beral V, Peterman T, Berkelman R, et al: AIDS associated non-Hodgkin's lymphoma. Lancet 337:805-809, 1991
4. Peters BS, Beck EJ, Coleman DG, et al: Changing disease patterns in patients with AIDS in a referral center in the United Kingdom: The changing face of AIDS. Br Med J 302:203-207, 1991
5. Pluda JM, Yarchoan R, Jaffe ES, et al: Development of non-Hodgkin's lymphoma in a cohort of patients with severe immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med 113:276-282, 1990
6. Moore RD, Keller H, Richman DD, et al: Non Hodgkin's lymphoma in patients with advanced HIV infection treated with zidovudine. JAMA 265:2208-2211, 1991
7. Levine AM, Bernstein L, Sullivan-Halley J, et al: Role of zidovudine antiretroviral therapy in the pathogenesis of acquired immunodeficiency syndrome-related lymphoma. Blood 86:4612-4616, 1995
8. Levine AM: Acquired immunodeficiency syndrome related lymphoma (review). Blood 80:8-20, 1992
9. Kaplan LD, Abrams DI, Feigal E, et al: AIDS associated non-Hodgkin's lymphoma in San Francisco. JAMA 261:719-724, 1989
10. Levine AM, Gill PS, Meyer PR, et al: Retrovirus and malignant lymphoma in homosexual men. JAMA 254:1921-1925, 1985
11. Knowles DM, Chamulak GA, Subar M, et al: Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS): The New York University experience. Ann Intern Med 108:744-753, 1988
12. Gill PS, Levine AM, Krailo M, et al: AIDS-related malignant lymphoma: Results of prospective treatment trials. J Clin Oncol 5:1322-1328, 1987
13. Dugan M, Subar M, Odajnyk C, et al: Intensive multiagent chemotherapy for AIDS related diffuse large cell lymphoma. Blood 68:124a, 1986 (abstr)
14. Levine AM, Wernz J, Kaplan L, et al: Low dose chemotherapy with central nervous system prophylaxis and azidothymidine maintenance in AIDS-related lymphoma: A prospective multi-institutional trial. JAMA 266:84-88, 1991
15. Walsh C, Wernz J, Levine AM, et al: Phase I study of m-BACOD and granulocyte-macrophage colony stimulating factor (GM-CSF) in HIV associated non-Hodgkin's lymphoma. J AIDS 6:265-271, 1993
16. Kaplan L, Straus D, Testa M, et al: Randomized trial of standard dose mBACOD with GM-CSF vs. reduced dose mBACOD for systemic HIV-associated lymphoma: ACTG 142. Proc Am Soc Clin Oncol 14:288, 1995 (abstr)
17. Sparano JA, Wiernik PH, Strack M, et al: Infusional cyclo-phosphamide, doxorubicin, and etoposide in human immunodeficiency virus and human T cell leukemia virus type I related non-Hodgkin's lymphoma: A highly active regimen. Blood 81:2810-2815, 1993
18. Straus D, Huang J, Testa M, et al: Prognostic factors in the treatment of HIV-associated non-Hodgkin's lymphomas: Analysis of ACTG 142 (low dose vs standard dose mBACOD + GM-CSF). Blood 86:604a, 1995 (abstr)
19. Von Hoff DD: MGBG: Teaching an old drug new tricks. Ann Oncol 5:487-493, 1994
20. Corti A, Dave C, Williamson-Ashman HG, et al: Specific inhibition of the enzymatic decarboxylation of S-adenosylmethionine by methylglyoxal bis (guanylhydrazone) and related substances. Biochem J 139:351-357, 1974
21. Pleshkewych A, Kramer DL, Kelly E, et al: Independence of drug action on mitochondria and polyamines in L1210 leukemia cells treated with methylglyoxal bis (guanylhydrazone). Cancer Res 40:4533-4540, 1980
22. Knight WA III, Livingston RB, Fabian C, et al: Phase I-II trial of MGBG: A Southwest Oncology Group pilot study. Cancer Treat Rep 63:1933-1937, 1979
23. 14. J Pharmacol 141:149-156, 1963
24. Marsh KS, Liesmann J, Patton TF, et al: Plasma levels and urinary excretion of methyl-GAG following IV infusion in man. Cancer Treat Rep 65:253-257, 1981
25. Knight WA III, Fabian C, Costanzi JT, et al: Methylglyoxal bis-guanyhydrazone (methyl GAG, MGBG), in lymphoma and Hodgkin's Disease. Invest New Drugs 1:225-237, 1983
26. Warrell RP, Lee BJ, Kempin ST, et al: Effectiveness of methyl-GAG (methylglyoxal-bis guanylhydrazone) in patients with advanced malignant lymphoma. Blood 57:1011-1014, 1985
27. Rosenblum MG, Stewart DJ, Yap BS, et al: Penetration of methylglyoxal bis (guanylhydrazone) into intracerebral tumors in humans. Cancer Res 41:459-462, 1981
28. Seppanen P, Alhonen-Hongisto L, Stimes M, et al: Quantitation of methyl glyoxal bis (guanylhydrazone) in blood plasma and leukemia cells of patients receiving the drug. Int J Cancer 26:571-576, 1980
29. Pathak SN, Dave C: Antagonism of methylglyoxal-bis-(guanylhydrazone) (MGBG) cytotoxicity by spermidine in mouse leukemia L1210 cells. Proc Am Assoc Cancer Res 18:184, 1977 (abstr)
30. Sartorelli AC, Ianotti AT, Booth BA, et al: Complex formation with DNA and inhibition of nucleic acid synthesis by methylglyoxal bis (guanylhydrazone). Biochim Biophys Acta 103:174-176, 1965
31. Pine MJ, DePaolo J: The antimitochondrial actions of 2-chloro-4′-4″-bis (2-imidazolin 2-yl)-terephtalanilide and methylglyoxal bis (guanyl-hydrazone). Cancer Res 26:18-25, 1966
32. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
33. McKelvy EM, Gottlieb JA, Wilson HE, et al: Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38:1484-1493, 1982
34. Schein PS, DeVita VT, Hubbard S, et al: Bleomycin, Adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of diffuse histiocytic lymphoma. Ann Intern Med 85:417-422, 1976
35. Velasquez WS, McLaughlin P, Tucker S, et al: ESHAP: An effective chemotherapy regimen in refractory and relapsing lymphoma. A 4-year follow-up study. J Clin Oncol 12:1169-1176, 1994
36. Mirza MR, Brincker H: MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study. Acta Oncol 30:17-21, 1991
37. Bagley CM, DeVita VT, Berard CW, et al: Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine and prednisone. Ann Intern Med 76:227-234, 1972
38. Levine AM, Sullivan-Halley J, Pike MC, et al: Human immunodeficiency virus related lymphoma: Prospective factors for survival. Cancer 68:2466-2472, 1991
39. Eron JJ, Benoit SL, Memsek J, et al: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 333:1662-1669, 1995
40. Danner SA, Carr A, Leonard JM, et al: A short term study of the safety, pharmacokinetics and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 333:1528-1533, 1995
41. Mellors JW, Rinaldo CJ Jr, Gupta P, et al: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170, 1996